1		SUPPORT INFORMATION	
2		for	
3	Tissue Dist	bution and Maternal Transfer of Poly- and Per-fluorinated Compounds in	n
4	Chinese Stu	geon (Acipenser sinensis): Implications for Reproductive Risk	
5	Hui PENG ¹	Qiwei WEI ² *, Yi WAN ³ , John P. GIESY ^{3,4} , Luoxin Li ² , and Jianying HU ¹ *	
6	¹ Laboratory	or Earth Surface Processes, College of Urban and Environmental Sciences	s,
7	Peking Univ	rsity, Beijing 100871, China	
8	² Laboratory	f Freshwater Biodiversity Conservation and Utilization, Ministry of Agricultur	e
9	of China; Y	igtze River Fisheries Research Institute, Chinese Academy of Fisheries Science	,
10	Jingzhou, H	pei 434000, China	
11	³ Departmen	of Veterinary Biomedical Sciences and Toxicology Centre, University of	of
12	Saskatchev	n, Saskatoon, Saskatchewan, S7J 5B3, Canada	
13	⁴ Zoology D	partment, Center for Integrative Toxicology, Michigan State University, East	st
14	Lansing, M	48824, USA	
15			
16			
17	Tables	4	
18	Figures	3	
19	Words	2383	
20			

This supporting information provides detailed descriptions of sample collection, artificial 21 22 fertilization, quantification of PFCs, quality assurance/quality control, correlation analysis between reproductive endpoints and PFAs, chromatograms of detected PFCs, and sensitivity 23 analysis of different PFAs. Figures, and tables addressing: (Table S1) details of Chinese 24 25 sturgeon samples; (Table S2) reproductive parameters of Chinese sturgeon; (Table S3) multiple reaction monitoring (MRM) of target PFCs; (Table S4) method detection limits 26 (MDLs) and recoveries; (Figure S1) chromatograms of detected PFCs; (Figure S2) 27 Correlations between concentrations (ng/g ww) of longer-chain PFCAs and PFOS in eggs and 28 age; (Figure S3) relative contributions to PFOS-EQ. 29

30

31 Chemicals and Reagents. Standards of the 23 target compounds (detailed information is

provided in Supporting Information) and three stable isotope labeled standards including 32 $1,2,3,4^{-13}C_4$ -perfluorooctanoic acid ($1,2,3,4^{-13}C_4$ -PFOA), $1,2,3,4^{-13}C_4$ -perfluorononanoic acid 33 $(1,2,3,4^{-13}C_4$ -PFNA), and $1,2,3,4^{-13}C_4$ -perfluorooctane sulfonate $(1,2,3,4^{-13}C_4$ -PFOS) were 34 35 purchased from Wellington Laboratories Inc. (Guelph, Ontario, Canada). All solvents, including methanol and methyl tert-butyl ether (MTBE), were all of HPLC grade and were 36 purchased from Fisher Chemicals (New Jersey, USA). Water was obtained from purification 37 of distilled water by a Milli-Q Synthesis water purification system (Millipore, Bedford, MA, 38 USA). 39

Quantification of PFCs and Quality Assurance/Quality Control. In brief, approximately 40 0.2-0.5 g of homogenized tissue was transferred to a 15 ml polypropylene (PP) centrifuge 41 tube. Fifty microliters (50 µl) of 20 µg/l mass-labeled internal standard 1,2,3,4-¹³C₄-PFOA, 42 1,2,3,4-¹³C₄-PFNA, and 1,2,3,4-¹³C₄-PFOS, 1 ml of 0.5 M tetrabutylammonium hydrogen 43 44 sulfate solution (TBAS), and 2 ml of 0.25 M sodium carbonate buffer were added for extraction. After mixing, 5 ml MTBE was added and the mixture was shaken for 20 minutes 45 at 300 rpm and then sonicated for 10 minutes. The organic layer was separated by 46 centrifugation at 3600 rpm for 15 min and then transferred to a second 15 ml PP tube. 47 Extraction was repeated twice and all three extracts were combined. The final extract was 48 blown to dryness under a gentle blow of nitrogen, and then reconstituted with 300 µl of 49 50 methanol and filtered through a 0.2 µm nylon mesh filter for analysis.

51 Aliquots of extracts were analyzed using a Waters ACQUITY UPLCTM system (Waters, 52 Milford, MA, USA) with a Waters Micromass Quattro Premier XE (triple-quadrapole) 53 detector operated in electrospray negative mode (ESI mode). Separation of PFCs was

S2

achieved with a Waters ACUITY UPLC BEH C18 column (1.7 µm; 2.1 mm × 100 mm), 54 preceded by a Waters ACUITY UPLC BEH C18 guard column (1.7 µm; 2.1 mm × 50 mm). 55 56 The guard column displaced the peaks caused by contamination from the HPLC such that 57 they did not interfere with the analytes in the samples. The injection volume was 5 μ l. Methanol (A) and 5 mM ammonium acetate (B) were used as the mobile phases. Initially 58 10% A was increased to 65% in 6 min, then increased to 75% at 7 min, a further 75% 59 methanol was increased to 100% over 4 min and kept for 2 min, followed by a decrease to 60 initial conditions of 10% A and held for 3 min to allow for equilibration. The flow rate was 61 The column and sample room temperatures were maintained at 40°C and 10°C, 0.2 mL/min. 62 63 respectively. Data were acquired under multiple reactions monitoring (MRM) mode and the 64 optimized parameters were described as follows: source temperature, 110°C; desolvation temperature, 350°C; capillary voltage, 2.50 kV; desolvation gas flow, 800 L/h; cone gas flow, 65 50 L/h; multiplier, 650 V (Table S3). 66

Since minor contamination of PFHxA was found during some batches, procedure blank 67 experiments were performed along with each batch of samples. Standard injections were 68 done among two or three sample injections, and methanol injections were done after each 69 standard injection to monitor background contamination. As for PFHxA with detectable 70 blank contamination, the method detection limits (MDLs) were defined to be three times the 71 72 procedure blanks, which ranged from 0.11 ng/g in the intestine to 0.36 ng/g in the egg. MDLs of other PFCs were defined for each tissue matrix as three times the noise, and ranged 73 from 0.02 ng/g for PFOSA to 1.8 ng/g for 6:2 FTCA (Table S4). The compound-specific 74 matrix spiking recoveries were determined for each organ by duplicates, and the values 75

76	ranged from 60% for 7:3 FTCA in the egg to 134% for FOSAA in the muscle.
77	Quantification was adjusted for recoveries by use of internal standards. Concentrations of
78	C ₆ -C ₈ PFCAs were corrected by ${}^{13}C_4$ -PFOA, C ₉₋ C ₁₄ (and C ₁₆) PFCAs by ${}^{13}C_4$ -PFNA, 6:2
79	FTUCA and 10:2 FTUCA by $^{13}C_2$ -6:2 FTUCA, 6:2 FTCA, 7:3 FTCA, 10:2 FTCA by
80	$^{13}C_2$ -6:2 FTCA, PFSAs and polyfluorinated amides by $^{13}C_4$ -PFOS, respectively. Average
81	recoveries for ${}^{13}C_4$ -PFOA, ${}^{13}C_4$ -PFNA, and ${}^{13}C_4$ -PFOS ranged from 69 ± 14% in the liver to
82	$87 \pm 14\%$ in the intestine, from $73 \pm 16\%$ in the egg to $98 \pm 13\%$ in the intestine, and from 77
83	\pm 13% in the muscle to 90 \pm 19% in the intestine, respectively. Average recoveries of ¹³ C ₂ -6:2
84	FTUCA and ${}^{13}C_2$ -6:2 FTCA in liver were 80 ± 6% and 81 ± 8%, respectively. Concentrations
85	of target analytes were determined based on calibration curves that were generated using
86	concentration series of 0, 20, 40, 80, 160, 320, 640, 1200, and 2400 pg/ml, which showed
87	strong linearity (correlation coefficients > 0.99).

88 Data Analysis. A one-way analysis of variance (ANOVA) was used to investigate the differences in concentrations of PFCs among tissues, and the Levene's test was used to check 89 equality of variances. Concentrations less than their respective method detection limits 90 (MDLs) were assigned a proxy value of MDL/2. Normal distributions of concentrations of 91 PFCs was determined by use of the Kolmogorov-Smirnov test. A log-transformation was 92 done to ensure the normality of the data distribution. Linear regression was performed to 93 94 evaluate relationships between concentrations of PFCs and age, the ratios of concentrations in the egg to those in the liver (ELRs), chain length, and protein-water partition coefficients (log 95 K_{pw}). All data analyses were performed with SPSS 15.0. 96

97 Relative Toxic Potencies (RPs) Calculations for Preliminary Risk Assessment. The RPs

98	of PFOA, PFNA, PFDA, PFDoDA, PFTeDA, PFHxDA and PFOS were obtained by
99	normalizing the PFAs EC_{50} concentrations of cytotoxicity to PFOS EC_{50} (EC_{50PFOS}/EC_{50PFA}).
100	The RPs of C ₇ PFCA, C ₈ PFCA, and C ₉ PFCA showed similar values which were 0.80, 1.00,
101	and 1.17, receptively. Greater RPs for C_{10} PFCA (6.55), C_{12} PFCA (6.68), and C_{14} PFCA
102	(7.64) compared to shorter carbon chain length were observed, showing similar RP values, but
103	that of C_{16} PFCA was relatively low (2.88). Such chain length-related toxicity has been
104	suggested to be the primary determinant of some types of toxicity of PFCs (7, 46), while it is
105	beyond the scope of this paper to discuss these relationships in detail. Since no QSAR data
106	for cytotoxicty of PFUnDA or PFTriDA were available, based on the similarity of RPs for
107	PFCA with chain length from 10 to 14, the mean (6.96) of C_{10} PFCA, C_{12} PFCA, and C_{14}
108	PFCA was used as those of PFUnDA and PFTriDA. RPs for PFOSA, FTCA and FTUCAs,
109	polyfluorinated amides, PFHpS and PFDS were ignored due to their low concentrations.
110	Concentrations of PFOS-EQ were calculated as the sum of the product of the concentration of
111	each PFC in egg multiplied by the respective RP, which ranged from 90.6 PFOS ng/g to 262
112	PFOS ng/g. These values were preferred to those derived from other endpoints because the
113	endpoint in the <i>in vitro</i> assays was cell lethality and the value to be predicted in Chinese
114	sturgeon was also lethality.

-							0 1
	Sample	Sex	Date of	Age	Body weight	Body length	Tissue collected
_	code		collection	(year)	(kg)	(cm)	
_	A0466	F	2003	24	254	285	L, St, I, Gi, K
	A0406	F	2004	18	174	245	E, M, H, Ov, St
	A0410	F	2004	17	140	246	E, L, M, H, Ov, St, I, Gb
	A0412	F	2004	24	230	287	E, L, M, H, St, I, Gi
	A0414	F	2004	25	263	285	E, L, I, Gi
	A0408	F	2004	22	230	258	E
	A0447	F	2005	19	192	247	E, L, M, H, Ov, I, Gi
	A0445	F	2005	18	187	237	L, M, H, Ov, I, Gi
	A0403	F	2005	24	260	280	E
	A0444	F	2005	23	224	270	E
	A0452	F	2005	23	207	282	E
	A0449	F	2005	22	252	275	E
	A0500	F	2005	22	227	261	E
	A0439	F	2006	21	223	262	E, L, M, H, St, I, Gi
	A0440	F	2006	17	176	250	E
	A0441	F	2006	24	240	300	E

120 SUPPORTING INFORMATION TABLE S1. Details of Chinese Sturgeon Samples.

E: egg; L: liver; M: muscle; H: heart; Ov: ovary^a; St: stomach; I: intestine; Gi: gill; K: kidney; Gb: gallbladder. a. ovary where the eggs has been fully released.

1 1 2

S6

	Fecundity	Fertilization	Survival	PFOS-EQ
	(kg^{-1})	(%)	(%)	(ng/g, ww)
A0444	1342	68.9	81.3	181.8
A0441	792	55.0	74.6	132.3
A0452	1266	76.3	89.0	147.5
A0403	1246	61.3	75.0	132.8
A0447	1041	19.6	34.0	169.2
A0449	940	58.3	71.9	170.3
A0500	1048	46.9	100	139.2

SUPPORTING INFORMATION TABLE S2. PFOS-EQ, Reproductive Parameters
(Fecundity^a, Fertilization^b, and Survival^c) in 7 Individuals.

148 a. egg numbers per weight; b. percentage of fertilized eggs in the total eggs; c. percentage of

the 5-day survival larval in the fertilized eggs

150

151

Compound	Acronym	Parent	Daughter	Cone	Collision
		Ion	Ion	Voltage	Energy
Perfluorohexanoate	PFHxA	313	269	14	22
Perfluoroheptanoate	PFHpA	363	319	17	9
Perfluorooctanoate	PFOA	413	369	15	10
Perfluorononanoate	PFNA	463	419	18	9
Perfluorodecanoate	PFDA	513	469	20	12
Perfluoroundecanoate	PFUnDA	563	519	20	13
Perfluorododecanoate	PFDoDA	613	569	23	11
Perfluorotridecanoate	PFTriDA	663	619	23	12
Perfluorotetradecanoate	PFTeDA	713	669	19	15
Perfluorohexadecanoate	PFHxDA	813	769	23	13
Perfluorohexane sulfonate	PFHxS	399	80	52	40
Perfluoroheptanesulfonate	PFHpS	449	80	50	40
Perfluorooctane sulfonate	PFOS	499	80	62	37
Perfluorodecane sulfonate	PFDS	599	80	75	45
7:3 fluorotelomer saturated					
carboxylate	7:3 FTCA	441	337	21	15
5:2 fluorotelomer saturated					
carboxylate	6:2 FTCA	377	63	12	8
6:2 fluorotelomer					
unsaturated carboxylate	6:2 FTUCA	357	293	16	16
10:2 fluorotelomer saturated					
carboxylate	10:2 FTCA	577	493	22	12
10:2 fluorotelomer					
unsaturated carboxylate	10:2 FTUCA	557	493	22	20
2-(perfluorooctane					
sulfonamido) acetic acid	FOSAA	556	498	45	24
2-(N-methylperfluorooctane					
sulfonamide) acetic acid	N-MeFOSAA	570	419	36	22
2-(N-ethylperfluorooctane					
sulfonamido) acetic acid	N-EtFOSAA	584	419	32	22
perfluorooctane sulfonamide	PFOSA	498	78	42	34

153 SUPPORTING INFORMATION TABLE S3. Multiple Reaction Monitoring (MRM)
154 Transitions of Poly- and Per-fluorinated Compounds (PFCs)

	E	Egg	Ι	Liver	Muscle		Ovary	
	MDLs	Recovery	MDLs	Recovery	MDLs	Recovery	MDLs	Recovery
PFHxA	0.36	73±5%	1.02	71 ± 9%	0.32	112±10%	0.28	96±3%
PFHpA	0.08	91±4%	0.10	122±1%	0.08	108±28%	0.10	90±6%
PFOA	0.11	66±1%	0.13	88±1%	0.07	78±5%	0.05	73±5%
PFNA	0.18	79±4%	0.09	107±4%	0.05	120±5%	0.10	101±5%
PFDA	0.18	74±4%	0.15	89±15%	0.05	112 ± 29%	0.05	101±1%
PFUnDA	0.10	87±7%	0.07	102 ± 7%	0.02	110 ± 22%	0.05	88±4%
PFDoDA	0.10	95±16%	0.08	102±31%	0.04	112 ± 9%	0.05	111 ± 7%
PFTriDA	0.10	81±2%	0.11	106±15%	0.05	96±10%	0.05	112±19%
PFTeDA	0.07	107±16%	0.12	118 ± 2%	0.06	102 ± 26%	0.08	71 ± 4%
PFHxDA	0.10	89±25%	0.07	100±14%	0.06	74±9%	0.06	67±1%
PFHxS	0.05	74±3%	0.13	99±9%	0.05	83±11%	0.05	80±2%
PFHpS	0.09	81±5%	0.09	84±10%	0.05	61±5%	0.06	70±4%
PFOS	0.18	102±6%	0.33	89±7%	0.05	85±14%	0.06	92±15%
PFDS	0.07	92±2%	0.04	93±2%	0.05	74±15%	0.05	67±2%
7:3 FTCA	0.08	72±3%	0.10	72±3%	0.06	100 ± 28%	0.07	68±5%
6:2 FTCA	1.8	60±10%	1.4	77±9%	1.1	83±8%	1.0	88±5%
6:2 FTUCA	0.35	107±2%	0.35	80±10%	0.20	75±15%	0.20	78±7%
10:2 FTCA	0.65	100±6%	0.57	83±5%	0.50	80±10%	0.53	98±8%
10:2 FTUCA	0.05	86±2%	0.10	82±7%	0.13	90±5%	0.22	91±7%
FOSAA	0.07	61±5%	0.06	85±10%	0.05	134 ± 24%	0.05	71±2%
N-MeFOSAA	0.07	64±8%	0.13	134±13%	0.06	95±21%	0.08	77±5%
N-EtFOSAA	0.06	85±7%	0.10	110 ± 6%	0.08	99±27%	0.05	81±3%
PFOSA	0.06	60±1%	0.05	82±1%	0.02	89±3%	0.07	79±1%
¹³ C ₄ -PFOA	/	69±14%	/	81±23%	/	77 ± 9%	/	74±5%
¹³ C ₄ -PFNA	/	73±16%	/	91±14%	/	84±18%	/	97±10%
¹³ C ₄ -PFOS ¹³ C ₂ -6:2	/	88±11%	/	88±18%	/	77±13%	/	79±4%
FTCA	/	/	/	81±8%	/	/	/	/
FTUCA	/	/	/	80±6%	/	/	/	/
	Ki	dney	Gal	lbladder	H	Heart	Int	estine
	MDLs	Recovery	MDLs	Recovery	MDLs	Recovery	MDLs	Recovery
PFHxA	0.12	85±19%	0.19	81±26%	0.21	96±22%	0.11	96±6%
PFHpA	0.12	100±4%	0.08	91±11%	0.08	86±7%	0.07	103±6%
PFOA	0.11	73±8%	0.06	76±7%	0.04	107±5%	0.05	71±3%
DENIA	0.11				0.05	107 + 107	0.05	108+4%
PFNA	0.11 0.14	116±24%	0.04	124±18%	0.05	10/±1%	0.05	100=170
PFNA PFDA	0.11 0.14 0.11	116±24% 104±14%	0.04 0.06	124±18% 120±13%	0.05	$107\pm1\%$ 108±10%	0.03	115±13%
PFNA PFDA PFUnDA	0.11 0.14 0.11 0.08	116±24% 104±14% 90±9%	0.04 0.06 0.05	124±18% 120±13% 90±11%	0.05 0.05 0.05	107±1% 108±10% 99±7%	0.05 0.10 0.05	115±13% 99±8%
PFNA PFDA PFUnDA PFDoDA	0.11 0.14 0.11 0.08 0.22	116±24% 104±14% 90±9% 96±17%	0.04 0.06 0.05 0.05	124±18% 120±13% 90±11% 96±6%	0.05 0.05 0.05 0.06	107±1% 108±10% 99±7% 117±14%	0.03 0.10 0.05 0.09	115±13% 99±8% 125±5%
PFNA PFDA PFUnDA PFDoDA PFTriDA	0.11 0.14 0.11 0.08 0.22 0.13	116±24% 104±14% 90±9% 96±17% 114±3%	0.04 0.06 0.05 0.05 0.05	124±18% 120±13% 90±11% 96±6% 112±1%	0.05 0.05 0.05 0.06 0.07	107±1% 108±10% 99±7% 117±14% 115±6%	0.03 0.10 0.05 0.09 0.05	115±13% 99±8% 125±5% 100±6%

SUPPORTING INFORMATION TABLE S4. Method Detection Limits (MDLs) (ng/g
ww) and Recoveries (n=2) of PFCs in Chinese Sturgeon.

PFHxDA	0.26	73±14%	0.07	87±11%	0.15	114 ± 21%	0.15	68±2%
PFHxS	0.10	80±2%	0.05	81±26%	0.07	78±2%	0.04	81±4%
PFHpS	0.1	74±4%	0.05	85±7%	0.10	92±4%	0.05	68±1%
PFOS	0.17	81±1%	0.05	90±8%	0.05	85±3%	0.11	81 ± 6%
PFDS	0.08	70±8%	0.09	79±11%	0.08	75±7%	0.07	72 ± 9%
7:3 FTCA	0.07	78±16%	0.06	80±8%	0.09	66±2%	0.07	77±1%
6:2 FTCA	1.0	76±8%	1.2	81±5%	0.95	90±10%	0.90	78±2%
6:2 FTUCA	0.23	82±6%	0.18	87±8%	0.13	88±7%	0.15	70±9%
10:2 FTCA	0.56	87±11%	0.68	77±5%	0.46	103±12%	0.55	81±2%
10:2 FTUCA	0.20	83±13%	0.10	89±10%	0.12	85±3%	0.07	86±10%
FOSAA	0.11	90±16%	0.04	63±13%	0.03	86±7%	0.03	80±1%
N-MeFOSAA	0.09	82±20%	0.04	84±18%	0.03	124±11%	0.06	112±1%
N-EtFOSAA	0.09	71±19%	0.08	61±4%	0.04	92±7%	0.08	117±1%
PFOSA	0.06	67±14%	0.02	67±9%	0.02	65±1%	0.02	74±1%
¹³ C ₄ -PFOA	/	71%	/	70%	/	82±15%	/	87±14%
¹³ C ₄ -PFNA	/	82%	/	81%	/	78±13%	/	98±13%
¹³ C ₄ -PFOS	/	79%	/	79%	/	83±7%	/	90±19%
$^{13}C_2-6:2$	-							
FTCA	/	/	/	/	/	/	/	/
C ₂ -6:2 FTUCA	/	/	/	/	/	/	/	/
	-		(Gill	Sto	omach		
			MDI	D		D		
			MDLS	Recovery	MDLS	Recovery		
		PFHxA	0.31	Recovery 124±16%	0.25	Recovery 102±10%		
	 H	PFHxA PFHpA	0.31 0.10	Recovery 124±16% 107±11%	0.25 0.07	Recovery 102±10% 85±11%		
	H	PFHxA PFHpA PFOA	0.31 0.10 0.08	Recovery 124±16% 107±11% 107±2%	0.25 0.07 0.06	Recovery 102±10% 85±11% 83±21%		
	H	PFHxA PFHpA PFOA PFNA	0.31 0.10 0.08 0.15	Recovery 124±16% 107±11% 107±2% 70±3%	MDLs 0.25 0.07 0.06 0.12	Recovery 102±10% 85±11% 83±21% 103±1%		
	H	PFHxA PFHpA PFOA PFNA PFDA	0.31 0.10 0.08 0.15 0.06	Recovery 124±16% 107±11% 107±2% 70±3% 117±23%	MDLs 0.25 0.07 0.06 0.12 0.07	Recovery 102±10% 85±11% 83±21% 103±1% 108±9%		
	I I P	PFHxA PFHpA PFOA PFNA PFDA FUnDA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9%		
	H H P P	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28%		
	I I P P P	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16%		
	P P P	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA FTeDA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4%		
	I I P P P P P	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA FTriDA FTeDA FTeDA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10%		
	F F P P P P	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA FTriDA FTreDA FHxDA PFHxS	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.10 0.05	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10%		
	I I P P P P I I	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA FTriDA FTeDA FHxDA PFHxS PFHpS	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07 0.05	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.05	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1%		
	I I P P P P I I I	PFHxA PFHpA PFOA PFDA FDnDA FDnDA FTriDA FTriDA FTreDA FHxDA PFHxS PFHpS PFOS	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07 0.05 0.09	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.10 0.05 0.05 0.05 0.05	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 62±1% 99±10%		
	I I P P P P I I I	PFHxA PFOA PFOA PFDA FDoDA FDoDA FTriDA FTriDA FTeDA FHxDA PFHxS PFHpS PFOS PFDS	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09 0.07 0.05 0.09 0.17	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.05 0.05 0.05 0.05 0.05 0.05	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1%		
	F F P P F 1 1 7:	PFHxA PFHpA PFOA PFNA PFDA FUnDA FDoDA FTriDA FTriDA FTeDA FHxDA PFHxS PFHpS PFHpS PFOS PFDS 3 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07 0.05 0.09 0.10 0.07	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1% 68±0.3%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.05 0.05 0.06 0.09 0.09	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 62±1% 99±10% 70±1% 74±9%		
	н Н Р Р Р Р Р Р 1 1 1 1 7: 6:	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTeDA FHxDA PFHxS PFHpS PFHpS PFOS PFDS 3 FTCA 2 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09 0.07 0.05 0.09 0.10 0.07 0.05 0.09 0.10 0.07	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1% 68±0.3% 76±7%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.05 0.06 0.09 1.0	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1% 74±9% 82±5%		
	I I P P P P I I I I I I I I I I I I I I	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTeDA FHxDA PFHxS PFHpS PFHpS PFOS PFDS 3 FTCA 2 FTCA 2 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07 0.05 0.09 0.10 0.07 0.8 0.15	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1% 68±0.3% 76±7% 83±7%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.05 0.06 0.05 0.06 0.05 0.06 0.09 1.0 0.15	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1% 74±9% 82±5% 73±4%		
	F F P P P P P F I I I I I I I I I I I I	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTeDA FTeDA FHxS PFHxS PFHpS PFHpS PFOS 3 FTCA 2 FTCA 2 FTCA 2 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.08 0.09 0.07 0.05 0.09 0.10 0.07 0.55 0.93 0.10 0.07 0.8 0.15 0.59	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 76±7% 83±7% 78±8%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.06 0.08 0.10 0.05 0.06 0.09 0.09 1.0 0.15 0.64	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1% 74±9% 82±5% 73±4% 82±9%		
	I I P P P P I I I I I I I I I I I I I I	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTreDA FTeDA FHxS PFHpS PFHpS PFDS 3 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09 0.09 0.07 0.05 0.09 0.10 0.07 0.31 0.10 0.07 0.8 0.15 0.59 0.27	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 76±7% 83±7% 78±8% 77±5%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.05 0.06 0.05 0.06 0.08 0.10 0.05 0.06 0.09 1.0 0.15 0.64 0.09	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1% 74±9% 82±5% 73±4% 82±9% 77±12%		
	F F F F F F F F F F F F	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTeDA FTeDA FHxS PFHxS PFHpS PFHpS PFOS 3 FTCA 2 FTCA 2 FTCA 2 FTUCA 2 FTUCA 5 OSAA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09 0.07 0.05 0.09 0.10 0.07 0.59 0.15 0.27 0.03	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1% 68±0.3% 76±7% 83±7% 78±8% 77±5% 81±4%	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.08 0.10 0.05 0.06 0.08 0.10 0.05 0.06 0.09 0.09 1.0 0.15 0.64 0.09 0.04	Recovery $102\pm10\%$ $85\pm11\%$ $83\pm21\%$ $103\pm1\%$ $108\pm9\%$ $81\pm9\%$ $103\pm28\%$ $79\pm16\%$ $102\pm4\%$ $81\pm10\%$ $82\pm10\%$ $62\pm1\%$ $99\pm10\%$ $70\pm1\%$ $74\pm9\%$ $82\pm5\%$ $73\pm4\%$ $82\pm9\%$ $77\pm12\%$ $82\pm16\%$		
	F F F F F F F F F F F N-M	PFHxA PFOA PFOA PFDA FDoDA FDoDA FDoDA FTriDA FTeDA FTriDA PFHxS PFHpS PFHpS PFDS 3 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA 2 FTCA	MDLs 0.31 0.10 0.08 0.15 0.06 0.08 0.08 0.09 0.09 0.07 0.05 0.09 0.10 0.07 0.8 0.15 0.59 0.27 0.03 0.06	Recovery 124±16% 107±11% 107±2% 70±3% 117±23% 105±6% 109±4% 119±8% 100±1% 114±3% 103±9% 77±1% 78±8% 77±1% 68±0.3% 76±7% 83±7% 78±8% 77±5% 81±4% 119±10	MDLs 0.25 0.07 0.06 0.12 0.07 0.04 0.05 0.06 0.05 0.06 0.05 0.06 0.09 1.0 0.15 0.64 0.09 0.04	Recovery 102±10% 85±11% 83±21% 103±1% 108±9% 81±9% 103±28% 79±16% 102±4% 81±10% 82±10% 62±1% 99±10% 70±1% 74±9% 82±5% 73±4% 82±9% 77±12% 82±16% 89±1%		

PFOSA	0.04	75±4%	0.02	64±11%
¹³ C ₄ -PFOA	/	80±16%	/	84±12%
¹³ C ₄ -PFNA	/	88±12%	/	83±15%
¹³ C ₄ -PFOS	/	89±8%	/	84±3%
$^{13}C_2-6:2$ FTCA $^{13}C_2-6:2$	/	/	/	/
FTUCA	/	/	/	/

	$^{100}_{\&}$ PFTeDA 713 > 669 S/N:PtP=203.60	¹⁰⁰ PFHxDA 813 > 769 S/N:PtP=86.44
	¹⁰⁰ ⊗ PFTriDA 663 > 619 S/N:PtP=558.40	¹⁰⁰ seN-EtFOSAA 584> 419 A S/N:PtP=19.84
	¹⁰⁰ 8 PFDoDA613 > 569 AS/N:PtP=72.71	¹⁰⁰ FOSAA 556 > 498 S/N:PtP=47.05
	¹⁰⁰ 8 PFUnDA563> 519 A S/N:PtP=189.82	¹⁰⁰ \approx 7:3 FTCA $441 > 337$ S/N:PtP=13.89
	¹⁰⁰ PFDA 513 > 469 A S/N:PtP=236.47	¹⁰⁰ SPFOSA 498> 78 AS/N:PtP=341.05
	¹⁰⁰ ⊗ PFNA 463 > 419 S/N:PtP=48.35	¹⁰⁰ se PFDS 599> 80 A S/N:PtP=92.24
	¹⁰⁰ 8 PFOA 413 > 369 S/N:PtP=29.68	¹⁰⁰ PFOS 499 > 80 A S/N:PtP =1698.50
	¹⁰⁰ ⊗ A PFHpA 363 > 319 S/N:PtP=24.46	¹⁰⁰ PFHxS 399 > 80 S/ N:PtP=7.08
180	8.00 8.40 8.80 9.20 9.60 10.00 10.40 10.8	0 7.50 8.00 8.50 9.00 9.50 10.00 10.50 11.00
181	SUPPORTING INFORMATION FIGUR	RE S1. Typical UPLC/MS/MS Chromatograms
182	of Detected PFCs in Chinese Sturgeon.	
183		
184		
185		
186		
187		
188		
189		
190		
191		



193 **SUPPORTING INFORMATION FIGURE S2.** Correlations between concentrations (ng/g 194 ww) of Longer-chain PFCAs and PFOS in eggs and age: $log_{10}C_{PFUnDA}=0.03\times age-0.10$, 195 $r^2=0.29$, p=0.049, $log_{10}C_{PFDoDA}=0.01\times age-0.09$, $r^2=0.02$, p=0.605, 196 $log_{10}C_{PFTriDA}=0.03\times age+0.44$, $r^2=0.25$, p=0.066, $log_{10}C_{PFTeDA}=0.02\times age-0.44$, $r^2=0.19$, 197 p=0.124, $log_{10}C_{PFOS}=-0.02\times age+1.44$, $r^2=0.03$, p=0.528.

199

200



203 SUPPORTING INFORMATION FIGURE S3. Relative Contribution of Each PFC to

204 PFOS-EQ in Eggs.